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Tumour angiogenesis plays a key role in tumour growth, formation of metastasis, detection and treatment of malignant
tumours. Recent investigations provided increasing evidence that quantitative analysis of tumour angiogenesis is an
indispensable prerequisite for developing novel treatment strategies such as anti-angiogenic and antivascular treatment options.
Therefore, it was our aim to establish and validate a new and versatile imaging technique, that is orthogonal polarisation
spectral
TM imaging, allowing for non-invasive quantitative imaging of tumour angiogenesis in vivo. Experiments were performed
in amelanotic melanoma A-MEL 3 implanted in a transparent dorsal skinfold chamber of the hamster. Starting at day 0 after
tumour cell implantation, animals were treated daily with the anti-angiogenic compound SU5416 (25 mg kg bw
71) or vehicle
(control) only. Functional vessel density, diameter of microvessels and red blood cell velocity were visualised by both
orthogonal polarisation spectral
TM imaging and ﬂuorescence microscopy and analysed using a digital image system. The
morphological and functional properties of the tumour microvasculature could be clearly identiﬁed by orthogonal polarisation
spectral
TM imaging. Data for functional vessel density correlated excellently with data obtained by ﬂuroescence microscopy
(y=0.99x+0.48, r
2=0.97, RS=0.98, precision: 8.22 cm
71 and bias: 70.32 cm
71). Correlation parameters for diameter of
microvessels and red blood cell velocity were similar (r
2=0.97, RS=0.99 and r
2=0.93, RS=0.94 for diameter of microvessels and
red blood cell velocity, respectively). Treatment with SU5416 reduced tumour angiogenesis. At day 3 and 6 after tumour cell
implantation, respectively, functional vessel density was 4.8+2.1 and 87.2+10.2 cm
71 compared to values of control animals
of 66.6+10.1 and 147.4+13.2 cm
71, respectively. In addition to the inhibition of tumour angiogenesis, tumour growth and
the development of metastasis was strongly reduced in SU5416 treated animals. This new approach enables non-invasive,
repeated and quantitative assessment of tumour vascular network and the effects of antiangiogenic treatment on tumour
vasculature in vivo. Thus, quantiﬁcation of tumour angiogenesis can be used to more accurately classify and monitor tumour
biologic characteristics, and to explore aggressiveness of tumours.
British Journal of Cancer (2002) 86, 1622–1627. DOI: 10.1038/sj/bjc/6600318 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: tumour microcirculation; OPS; angiogenesis
The formation of new blood vessels, angiogenesis, is a prerequisite
for the growth of solid tumours and forms the basis for new anti-
vascular treatment strategies (Folkman, 1995). Quantitative analysis
of tumour vascularity is of paramount importance for the assess-
ment of microvascular function and for the development of
novel antivascular treatment strategies. Targeting of the angiogenic
pathway to inhibit neovascularisation is a promising new develop-
ment for the treatment of solid tumours and the prevention of
metastasis (O’Reilly et al, 1996, 1997; Bergers et al, 1999). A prere-
quisite for monitoring angiogenic activity of tumours in vivo, thus
investigating the success of such a therapy, is the availability of a
quantitative angiogenesis assay (Jain et al, 1997).
Currently, however, knowledge about tumour angiogenesis is
mainly obtained either by counting the microvessel density of
biopsied tumours (Weidner et al, 1991) or by immunohistological
analysis of angiogenic factors such as VEGF (Gasparini et al, 1997).
The drawback to these techniques is that they are invasive, one-
point measurements and limited to regions of the tumour which
are biopsied.
Orthogonal polarisation spectral
TM (OPS) imaging is a novel
technique which has been introduced recently to visualise micro-
vessels in vivo where tissue is illuminated with linearly polarised
light and imaged through a polariser oriented orthogonal to the
plane of the illuminating light (Groner et al, 1999). Using this
technique close to wavelengths within the haemoglobin absorption
spectrum, microvessels containing red blood cells can be visualised.
The OPS imaging system does not require transillumination or
ﬂuorescent dyes for contrast enhancement and can be positioned
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www.bjcancer.comdirectly on top of the tumour to visualise tumour vessels. The
small size of the probe facilitates its use as a non-invasive diagnos-
tic tool not only experimentally but more importantly in clinical
settings to evaluate and monitor tumour angiogenesis (Figure
1A). In fact, images of a human squamous cell carcinoma of the
tongue and of normal tongue microcirculation can be obtained
using OPS imaging, as shown in Figure 1B,C.
Therefore, it was our aim to evaluate and validate the OPS
imaging system with regard to the speciﬁc heterogenous tumour
vascularity. Animals bearing solid tumours were treated with
anti-angiogenic therapy using the synthetic FLK-1 kinase inhibitor
SU5416 (Sugen Inc., San Francisco, CA, USA) to block the signal
transduction pathway through the VEGF receptor (Fong et al,
1999; Vajkoczy et al, 1999). Tumour angiogenesis was quantiﬁed
by OPS imaging and compared with simultaneous intravital ﬂuor-
escence microscopy investigations for the quantiﬁcation of tumour
angiogenesis and tumour microhaemodynamics. This novel techni-
que allows to quantify noninvasively morphological and functional
tumour vascularity. Moreover, OPS imaging allows for assessment
of tumour angiogenesis in a clinical setting to assess prognosis of
patients and to monitor antivascular and anti-angiogenic treatment
regimes.
MATERIALS AND METHODS
Animal and tumour model
Following approval of the local ethics committee experiments were
performed on male Syrian golden hamsters (50–60 g body
weight). The ethical guidelines that were followed meet the stan-
dards required by the the UKCCCR ‘Guidelines for the welfare
of animals in experimental neoplasia’ (Workman et al, 1998).
Experiments were performed with male Syrian Golden hamsters
(40–60 g body weight) obtained from Charles River (Sulzbach,
Germany). They were kept in a normal 12 h light:12 h dark cycle
and fed laboratory chow (ssniff; Spezialdiaeten GmbH, Soest,
Germany) ad libitum and had free access to drinking water. For
the microsurgical procedure, the hamsters were anaesthetised by
intraperitoneal injection of ketamine (100 mg kg
71 body weight,
Ketavet; Parke-Davis, Berlin, Germany) and xylazine (10 mg kg
71
body weight, Rompun; Bayer, Leverkusen, Germany). Dorsal skin
was shaven and chemically depilated (Pilcamed; Schwarzkopf,
Hamburg, Germany). The dorsal skinfold chamber (Asaishi et al,
1981; Endrich et al, 1982) was implanted by sandwiching the
extended double layer of dorsal skin between two symmetrical tita-
nium frames. Twenty-four hours after chamber preparation
2610
5 cells of the amelanotic melanoma of the hamster A-Mel-3
were implanted into each chamber (Fortner et al, 1961; Endrich
et al, 1982). After 48 h a ﬁne polyethylene catheter was inserted
into the jugular vein for injection of ﬂuorescent dyes.
Anti-angiogenic treatment
After tumour cell implantation, animals were assigned randomly to
two groups. Starting on the day of tumour implantation, animals
(n=8) were treated daily by intraperitoneal injection of SU5416
twice (Sugen Inc., San Francisco, CA, USA) dissolved in DMSO
at a ﬁnal concentration of 25 mg kg
71 body weight. This dosage
of SU5416 has been proven to be effective previously in several
different animal species (Fong et al, 1999). The control animals
(n=8) received the DMSO only.
Simultaneous assessment of tumour angiogenesis by
intravital microscopy and by OPS imaging
Tumour angiogenesis was quantiﬁed at days 3, 6, 9 after tumour
implantation. For the experiments, the awake animals were immo-
bilised in a plexiglass tube and the chamber preparation was
attached to a microscope stage, which was computer controlled
to allow for repeated scanning of identical segments of microves-
sels. To take advantage of the computer controlled microscope
functions the OPS imaging probe was attached to the shaft of
the microscope. The plexiglas stage was modiﬁed so that there were
two different pairs of holes, with which the stage could be attached
to the motorised plate. One pair of holes aligned the chamber
under the ﬂuorescence microscope and the other set aligned the
chamber under the OPS imaging probe. Moving the stage from
one pair of holes to the other, the identical region of interest could
be observed with the two systems. OPS imaging was using the new
Cytoscan E-II instrument (Cytometrics Inc., Philadelphia, PA,
USA) (Harris et al, 2000) with a ﬁnal magniﬁcation of 4626.
The measurement depth of OPS imaging at this magnitude is
approximately 300 mm. Validation of OPS imaging was performed
with ﬂuorescence microscopy using 100 mg kg
71 b.w. ﬂuorescein
isothiocyanate-labelled dextran (FITC-dextran, Mr=500,000 Sigma
Chemie, Deisenhofen, Germany) for visualisation of microvessels.
For ﬂuorescence microscopy a 20-fold water immersion objective
(Zeiss Axiotech 100 HD microscope, Acroplan 206/0.5 W, Zeiss,
Oberkochen, Germany) with a total magniﬁcation of 5336 was
used. A 150 W halogen lamp (Schott 1500, Schott, Mainz,
Germany) in combination with a ﬂuorescence ﬁlter block (excita-
tion: 450–490 nm, emission 4520 nm) was used to visualise
FITC-Dextran. Fluorescence images were captured using a
charge-coupled device video camera (FK 6990 IQ-S, Piper,
Schwerte, Germany). The images from both devices (Cytoscan A/
R and ﬂuorescence microscopy) were recorded on S-VHS video
tape (video recorder SVO-9500 MDP, Sony, Koeln, Germany) for
later off-line analysis.
Six regions of interest (ROI), three from the centre of the
tumour and three from the periphery of the tumour, were
randomly selected for the assessment of tumour angiogenesis.
Analysis of microcirculatory parameters using OPS imaging as well
as ﬂuorescence microscopy were performed off-line from the video-
tapes by digital image analysis system (Cap-Image, Ingeneurbuero
Zeintl, Heidelberg, Germany). Functional vessel density (fvd) as
parameter of tumour angiogenesis (one per cm), deﬁned as the
total length of perfused microvessels per unit area of observation,
was quantiﬁed (Dellian et al, 1996). For microhaemodynamic
measurements, the diameter (d) of microvessels (mm) and red
blood cell velocity (VRBC,m ms
71) were measured.
Evaluation of tumour growth and metastasis formation
For tumour implantation animals were anaesthesised as described
above. The dorsal skin of the animals was shaven and depilated.
A total of 5610
6 cells of the amelanotic melanoma A-MEL-3
suspended in a volume of 10 ml RPMI-1640 medium (Biochrom,
Berlin, Germany) were injected subcutaneously in the dorsal skin
of hamsters (Kuhnle et al, 1992). Tumour diameters, body weight
and axillar and inguinal metastasis presence were determined at 2
days intervals beginning at day 3 after tumour implantation. For
tumour diameter measurements the longer (l) and shorter (w)
perpendicular axes and the height (h) of each tumour were quan-
tiﬁed by a caliper (Dellian et al, 1994). Individual tumour volume
was calculated using the formula C6length6weight6height,
where C has been empirically determined as 0.873, assuming a
speciﬁc tumour tissue density of 1 g cm
72.
Statistics
Data are expressed as mean+s.e.mean. Nonparametric one-way
analysis of variance and multiple comparison on ranks of several
independent samples were performed using the Kruskal–Wallis
test. Single comparisons of related samples were executed using
the Friedman repeated measures on ranks followed by the post-
hoc Dunn’s test. Independent samples were tested using the
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(10), 1622–1627Wilcoxon–Mann–Whitney U-test followed by the Bonferroni–
Holm test. Relation between both techniques was analysed by the
Spearman correlation coefﬁcient Rs and linear regression. Agree-
ment between the two methods was evaluated as bias and
precision as described by Bland and Altman (1986). A P-value less
than 0.05 was regarded as statistically signiﬁcant.
RESULTS
OPS imaging
The morphological features of the tumour microvasculature were
clearly identiﬁed by OPS imaging. Figure 2 shows representative
corresponding images of the tumour microvessels obtained by
OPS imaging (Figure 2A,C) and by intravital ﬂuorescence micro-
scopy using ﬂuorescence labelled dextran as a plasma marker to
contrast the microvessels (Figure 2B,D). The vasculature of the
tumour is characterised by irregular angio-architecture and hetero-
geneities of blood perfusion. Tumours of animals treated with
SU5416 had reduced angiogenic activity quantiﬁed by functional
microvessel density (Figure 2A,B), compared to controls (Figure
2C,D).
The ability of OPS imaging to analyse tumour angiogenesis was
validated by quantifying the functional vessel density, deﬁned as
the length of red blood cell perfused capillaries per observation
area. Results obtained were compared with data obtained by ﬂuor-
escence microscopy which is regarded as gold standard for such
measurements. Data of functional microvessel density obtained
by the two methods revealed an excellent correlation for the
tumours investigated (y=0.99x+0.48, r
2=0.97, RS=0.98, P50.05,
n=180, Figure 3A). Precision and bias calculated by the Bland–
Altman analysis between these two measurements techniques was
8.22 and 70.32 cm
71, respectively (Figure 3B).
In addition to morphological features, OPS imaging offers the
potential to monitor noninvasively and continuously the microhae-
modynamics of tumours. Therefore, we compared diameter and
red blood velocity of tumour microvessels with data obtained by
intravital ﬂuorescence microscopy. The correlations were excellent
for measurements of red blood cell velocity (y=1.03x70.0002,
r
2=0.97, RS=0.99, P50.05, n=268, Figure 4A) with a precision of
0.021 and a bias of 0.002 mm s
71 between both methods (Figure
4B), and for measurements of microvessel diameter
(y=0.87x71.25, r
2=0.93, RS=0.94, P50.05, precision: 2.3 mm, bias:
3.5, n=268).
Tumour angiogenesis and microhaemodynamics
Treatment of tumours with SU5416 reduced the formation of
new vessels. The functional vessel density of tumours monitored
by OPS for control and SU5416 treated animals, respectively,
was 66.6+10.1 and 4.8+2.1 cm
71 at day 3 after tumour cell
implantation (P50.05), 147.4+13.2 and 87.2+10.2 cm
71 at
day 6 (P50.05), and 119.7+7.2 and 106.1+14.7 cm
71 at day
9 (Figure 5A). With respect to red blood cell velocity there
were no signiﬁcant differences between the groups: Red blood
cell velocity was 0.09+0.03 and 0.03+0.01 mm s
71 at day 3,
0.08+0.02 and 0.11+0.04 mm s
71 at day 6, and 0.09+0.02
and 0.07+0.02 mm s
71 at day 9 after tumour cell implantation,
for control and SU5416 treated animals, respectively. Similarly,
no effect of SU5416 treatment on microvascular diameter could
be noted. Microvessel diameter was 17.6+2.1 and 12.6+3.8 mm
at day 3, 14.5+1.4 and 15.2+1.5 mm at day 6, and 16.6+0.4
and 15.3+2.5 mm at day 9 after tumour cell implantation, for
control and SU5416 treated animals, respectively.
Tumour growth and metastasis development
Exponential tumour growth was observed in all tumours of
control animals. In addition to the inhibition of new vessel
formation, daily treatment of animals with SU5416 resulted in
a signiﬁcant delay of tumour growth (Figure 5B). At the end
of the observation period, 19 days after tumour cell implanta-
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Figure 1 (A) Orthogonal polarization spectral (OPS
TM) imaging probe. (B) Representative OPS image of a tongue tumour acquired from a patient.
Tumour microvessels can be clearly depicted. (C) Representative OPS image of normal tongue microcirculation.
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3 for control vs
1.2+0.2 cm
3 for anti-angiogenic treated animals. There was no
difference in animal body weight over the whole period of obser-
vation. Axillary metastases became palpable in all control animals
between day 9 and day 11 after tumour cell implantation. In the
SU5416 group, only in one animal axillary metastasis formation
was palpable at day 19 after tumour cell implantation. Total
volume of axillary metastasis at the end of the investigation
was 1.09+0.31 vs 0.05+0.05 cm
3 for control and SU5416 treated
animals, respectively.
DISCUSSION
OPS imaging
OPS imaging is a new technique to visualise microvessels in vivo.
We have established and validated this new technique for the
tumour microvasculature to allow for characterisation of angiogen-
esis and the effects of anti-angiogenic treatment of tumours.
Simultaneous measurements by OPS imaging were compared with
intravital ﬂuorescence microscopy investigations of tumour angio-
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Figure 2 Representative images of tumour microvasculature in animals treated with SU5416 (25 mg kg
71 per day, A,B) and with vehicle (C,D) at day 6
after tumour cell implantation. Corresponding regions by means of OPS imaging (A,C) and ﬂuorescence microscopy (B,D). Arrows indicate non perfused
vessels.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(10), 1622–1627genesis, red blood velocity and vessel diameter. For microvessel
density, a well established parameter for tumour angiogenesis
(Dellian et al, 1996; Jain et al, 1997) excellent correlation para-
meters were found. Furthermore, OPS imaging demonstrated
high precision for measurements of red blood cell velocity and
microvessel diameter. This issue is of paramount interest because
nutritive perfusion not only depends upon the morphological
properties of the network of exchange vessels, but also on func-
tional parameters such as red blood velocity and distances
between exchange vessels (Intaglietta and Zweifach, 1974). The
additional assessment of microhaemodynamic response to antivas-
cular or anti-angiogenic therapies is of major interest when these
treatment modalities are combined with different treatment
options relying on an intact tumour vasculature such as
chemotherapy or radiation therapy (Mauveri et al, 1998). However,
for measurements of microvessel diameter, parameters assessed for
correlation differed. The slope of the linear regression curve was
0.87 with an systematic bias of 3.5 mm indicating an underestima-
tion in the measurements by OPS compared to ﬂuorescence
microscopy. This systematic difference is to be expected given
the nature of the measurements with ﬂuorescence microscopy.
Due to light scattering of the ﬂuorescence light microvessel
diameters are overestimated 15% which is in agreement with
previous investigations (Gretz and Duling, 1995). Furthermore,
streaming of red blood cell velocity in the centre of the vessel
potentially contributes to the underestimation of microvessel
diameter measurements in OPS imaging. The data are in good
aggreement with a previous validation study comparing OPS
imaging with intravital microscopy with respect to hepatic micro-
circulation (Langer et al, 2001).
The present study supports SU5416 as a potent synthetic inhibi-
tor of angiogenesis by blocking the VEGF/Flk-1 signal transduction
pathway. This compound, which is currently under investigation in
Phase III clinical studies for the treatment of human tumours, has
been shown to have anti-angiogenic properties and broad antitu-
mour effects leading to a reduction of tumour growth (Fong et
al, 1999). The inhibition of tumour angiogenesis as quantiﬁed by
functional vessel density using OPS imaging was accompanied by
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British Journal of Cancer (2002) 86(10), 1622–1627 ã 2002 Cancer Research UKa sharp reduction in tumour growth and, in the formation of
metastasis. However, the inhibition of tumour angiogenesis was
only signiﬁcant on day 3 and 6 after tumour implantation. Other
mechanism of tumour angiogenesis than the VEGF mediated signal
transduction pathway might lead to the delayed formation of new
tumour vessels.
Implications
OPS imaging technology provides a new method for the assessment
of tumour microvessels in vivo. The small size of the probe facili-
tates its use as a non-invasive diagnostic tool in both
experimental and clinical settings to evaluate and monitor angio-
genesis/angiogenic activity of tumours known to impact the
prognosis of the disease. The ability to obtain high contrast images
of the vasculature using reﬂected light will allow for a non-invasive
and repetetive quantitative measurement of the distinct morpholgi-
cal speciﬁties of the new vasculature such as vascular volume,
surface and density as well as quantitative information about the
functional characteristics of vasculature with parameters like micro-
vessel density, and vascular dynamics which are both important
requirements for angiogenesis assays (Jain et al, 1997). The small
size and portability of the OPS imaging device compared to normal
intravital microscopes makes it possible to use the instrument easily
in a clinical setting. As it can be seen in Figure 1B,C, the image
quality obtained in a human squamous cell carcinoma of the
tongue and in normal tongue microcirculation is comparable to
that seen in this study. Quantitative knowledge about angiogenic
activity will form the basis for monitoring selective anti-angiogenic
and antivascular cancer treatment options in the future.
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